Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer

Completed · Phase 1

Conditions studied: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm

In brief

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced hematologic cancer.

Key facts

Study ID

NCT00003395

Run by

Memorial Sloan Kettering Cancer Center

Starts

1998-04-01

Expected to finish

2000-03-01

Last updated by the study team

2013-06-25

Who can join

Age: 17 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.